Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study

INTRODUCTION: ‘REASSURE’ (NCT01377012), a phase 3 study, evaluated the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to, or intolerance of, tumor necrosis factor inhibitors (TNF-inhibitors). METHODS: A total of 637 patients were r...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahir, Hasan, Deodhar, Atul, Genovese, Mark, Takeuchi, Tsutomu, Aelion, Jacob, Van den Bosch, Filip, Haemmerle, Sibylle, Richards, Hanno B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696298/
https://www.ncbi.nlm.nih.gov/pubmed/29138986
http://dx.doi.org/10.1007/s40744-017-0086-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696298/
https://www.ncbi.nlm.nih.gov/pubmed/29138986
http://dx.doi.org/10.1007/s40744-017-0086-y

Ejemplares similares